Vir Biotechnology, Inc. officer Vanina de Verneuil filed a Form 144 notice on November 2, 2026, proposing the sale of 1,343 shares of common stock acquired through restricted stock vesting, with an aggregate market value of $15,221.96.
Key Highlights
- Filer and role: Vanina de Verneuil (also signed as Vanina Huard de Verneuil) is identified as an officer of Vir Biotechnology, Inc.
- Shares proposed for sale: 1,343 shares of common stock, with an aggregate market value of $15,221.96.
- Acquisition method: The shares were acquired through restricted stock vesting from the issuer on November 2, 2026, classified as compensation.
- Purpose of sale: According to the filing, the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
- Shares outstanding: The filing lists 169,215,958 shares of common stock outstanding.
- Prior sales: The filing reports nothing to report for securities sold during the past 3 months.
- Exchange and broker: The proposed sale is to occur on NASDAQ, through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.
Form 144 Notice: Officer Proposes Tax-Related Sale Following Restricted Stock Vesting
Vir Biotechnology, Inc. (NASDAQ:VIR), headquartered at 1800 Owens Street, Suite 900, San Francisco, California 94158, is the issuer named in this Form 144 filing. The notice was submitted on November 2, 2026, by Vanina de Verneuil, identified in the filing as an officer of the company. The proposed sale covers 1,343 shares of common stock, representing an aggregate market value of $15,221.96 based on figures provided in the filing.
According to the filing, the shares were acquired on November 2, 2026, through a restricted stock vesting transaction from the issuer, with the nature of payment listed as compensation. The filing notes in the remarks section that the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," indicating a tax-withholding purpose for the proposed sale. No prior sales of the issuer's securities were reported by the filer during the preceding three months.
The filing was signed by Daniel Tucci, described as "a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Vanina Huard de Verneuil." As of the filing date, the total number of shares of common stock outstanding is reported as 169,215,958. The SEC file number for Vir Biotechnology, Inc. is listed as 001-39083.
What Was Disclosed
A Form 144 notice was filed on November 2, 2026, on behalf of Vir Biotechnology officer Vanina de Verneuil, proposing the sale of 1,343 restricted stock vesting shares with an aggregate market value of $15,221.96, attributed to covering a tax obligation from a vested equity award.



Please wait processing your request...